We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Technopath Clinical Diagnostics - An LGC Company

Download Mobile App


ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.

High-Sensitivity Troponin I Could Predict Preeclampsia in High-Risk Women

By LabMedica International staff writers
Posted on 16 Mar 2023
Print article
Image: Elevated hs-cTnI levels can precede and predict pre-eclampsia (Photo courtesy of Pexels)
Image: Elevated hs-cTnI levels can precede and predict pre-eclampsia (Photo courtesy of Pexels)

Pre-eclampsia is a dangerous pregnancy complication characterized by high blood pressure that complicates up to 8% of pregnancies, although data on biomarkers that can predict onset and disease severity has so far been limited. Now, a new study has found High Sensitivity Cardiac Troponin I (hs-cTnI) to be significantly higher in pregnant women who go on to develop preeclampsia starting at 14 weeks.

The multi-center observational study by researchers at University Heart Center Freiburg (Freiburg, Germany) involved four international cohorts of pregnant women (SCOPE, MAViS, PRINCE, and OCC) and examined the relation between high-sensitivity troponin and pre-eclampsia onset and severity using the Abbott hs-cTnI assay. The preeclampsia definition varied based on cohort (PRINCE utilizing GSGO guidelines, MAViS and SCOPE utilizing ISSHP, and OCC utilizing DSOG). Severe preeclampsia was defined as preeclampsia requiring delivery <34 weeks gestation; high preeclampsia risk was defined as anyone meeting NICE guidelines for prophylactic aspirin.

A total of 2,293 pregnant women were included in the study, with 7.8% of them developing preeclampsia and 0.9% developing severe preeclampsia. Of the total, 17.3% were identified as high-risk prior to the start of the study, and the average age of the women was 32 years. Women who developed preeclampsia had a higher prevalence of hypertension, diabetes, African American ancestry, and a history of multiple pregnancies. hs-cTnI levels were persistently high in women who ultimately developed preeclampsia, starting from 14 weeks (and lasting up to 29 weeks) of gestational age (all p<0.001) in the women who ultimately developed preeclampsia (all p<0.001). A hs-cTnI cutoff value of >2.2pg/ml at 14 weeks and >2.6pg/ml at 26 weeks was found to have a combined 100% negative predictive value in predicting severe preeclampsia in women who had a high a priori risk (meeting NICE criteria). Additionally, a hs-cTnI cutoff value of >1.8pg/ml at 14 weeks and >1.9pg/ml at 26 weeks predicted the presence of any preeclampsia.

“Elevated levels of hs-cTnI may precede the development of preeclampsia….and may also have considerable potential in grading preeclampsia risk [and severity] in pregnant women…a randomized, prospective trial needs to assess the potential benefits,” stated Dr. Dirk Westermann from the University Heart Center Freiburg who led the research team.

Related Links:
University Heart Center Freiburg

Gold Supplier
Urinalysis Dipstick Control
Dipper Urinalysis Dipstick Control
Rapid Saliva-Based Pregnancy Test
Multi-Drug Rapid Test
Multi-Drug Rapid Test
Automated Electrolyte Analyzer

Print article


Clinical Chem.

view channel
Image: Brief schematic diagram of the detection principle and method (Photo courtesy of CAS)

Rapid, Non-Invasive Method Diagnoses Type 2 Diabetes by Sniffing Urinary Acetone

Over 90% of diabetes cases are attributed to Type 2 diabetes (T2D), a prevalent metabolic condition that is expected to impact 380 million individuals globally by 2025. Despite being highly accurate, the... Read more


view channel
Image: A genetic test could guide the use of cancer chemotherapy (Photo courtesy of Pexels)

Genetic Test Predicts Whether Bowel Cancer Patients Can Benefit From Chemotherapy

Late-stage bowel cancer patients usually undergo a series of chemotherapies and targeted medicines for cancer treatment. However, the responses to the last-line chemotherapy treatment trifluridine/tipiracil... Read more


view channel
Image: Sampling a single stool using multiple PCR panels can identify more pathogens rapidly (Photo courtesy of Pexels)

PCR Panels for Acute GI Infections Can Lower Costs, Hospitalization and Antibiotic Use

Acute gastroenteritis impacts adults across all age groups and incurs enormous healthcare expenses. Now, a new study comprising 40,000 hospital visits across various geographic locations has revealed that... Read more


view channel
Image: Artificial intelligence predicts genetics of cancerous brain tumors in under 90 seconds (Photo courtesy of Michigan Medicine)

AI-Based Diagnostic Screening System Predicts Genetics of Cancerous Brain Tumors in 90 Seconds

The diagnosis and treatment of gliomas increasingly rely on molecular classification, as surgical benefits and risks vary depending on a patient's genetic makeup. Complete removal of the tumor can extend... Read more


view channel
Image: Live view of non-fluorescent specimens using the glowscope frame (Photo courtesy of Winona State University)

Device Converts Smartphone into Fluorescence Microscope for Just USD 50

Fluorescence microscopes are utilized to examine specimens labeled with fluorescent stains or expressing fluorescent proteins, like those tagged with green fluorescent protein. However, since these microscopes... Read more


view channel
Image: Roche and Lilly will collaborate on the development of Roche Diagnostics’ Elecsys Amyloid Plasma Panel (Photo courtesy of Roche)

Roche and Eli Lilly Collaborate on Innovative Blood Test for Early Diagnosis of Alzheimer's

Presently, obstacles to timely and precise diagnosis of Alzheimer's disease exist globally, resulting in as many as 75% of individuals exhibiting symptoms but lacking a formal diagnosis.... Read more
Copyright © 2000-2023 Globetech Media. All rights reserved.